计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| I411993-100μg |
100μg |
现货 ![]() |
| |
| I411993-1mg |
1mg |
现货 ![]() |
| |
| I411993-5mg |
5mg |
现货 ![]() |
| |
| I411993-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Ipilimumab (anti-CTLA-4), 细胞毒性 T 淋巴细胞相关蛋白 4 (CD152) 抗体 |
|---|---|
| 别名 | 伊匹单抗(抗 CTLA-4) |
| 英文别名 | MDX-010 | BMS-734016 | Yervoy | Ipilimumab | Ipilimumab (anti-CTLA-4) | Recombinant Ipilimumab Antibody | Ipilimumab (MDX-010) | ALPS5 antibody | CD 152 antibody | CD antibody | CD152 antibody | CD152 antigen antibody | CD152 isoform antibody | Celiac dis |
| 规格或纯度 | 无载体, 重组, ExactAb™, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | CTLA-4/CD152 |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | 人(Human),小鼠(Mouse),食蟹猴(Cynomolgus monkey) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 细胞毒性 T 淋巴细胞相关蛋白 4 (CD152) 抗体 |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | 重组抗体 |
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 26.9 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 176.3 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% (SDS-PAGE&SEC) |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 477202-00-9 |
| 分子类型 | 抗体 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
Ipilimumab (anti-CTLA-4) (I411993) - ELISA
Immobilized Hu-CTLA-4-His at 2 μg/mL can bind Ipilimumab (anti-CTLA-4) (I411993) with the EC₅₀ of 6.69 ng/mL.
Ipilimumab (anti-CTLA-4) (I411993) - SEC
The purity of Ipilimumab (anti-CTLA-4) (I411993) is more than 95% verified by HPLC.
Ipilimumab (anti-CTLA-4) (I411993) - ELISA
Immobilized Recombinant Human CTLA4 protein (rp176276) at 1.0 μg/mL can bind Ipilimumab (anti-CTLA-4) (I411993) with the EC₅₀ of 19.03 ng/mL.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | I411993 | |
| 分析证书 | I411993 | |
| 分析证书 | I411993 | |
| 分析证书 | I411993 | |
| 分析证书 | I411993 | |
| 分析证书 | I411993 |
¥539.90
¥499.90
¥279.92
¥669.90
¥669.90
¥463.92
| 1. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al.. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.. N Engl J Med, 372 (21): (2006-17). [PMID:25891304] |
| 2. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al.. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.. N Engl J Med, 373 (1): (23-34). [PMID:26027431] |
| 3. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al.. (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.. N Engl J Med, 378 (14): (1277-1290). [PMID:29562145] |